A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma

ObjectivesTo perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pNx), even in the absence of pathologically confirmed nodal metastases (pN0).MethodsWithin the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan–Meier plots. Univariable and multivariable Cox regression models tested the effect of N0 vs Nx stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery.ResultsThe CSM-free survival rate at 5 years after NU was 81.2% and 77.8% respectively for pN0 and pNx patients. In univariable analyses pNx vs pN0 status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pNx vs pN0 status still failed to achieve independent predictor status (HR: 0.99; P = .9).ConclusionsWe found no survival benefit related to the performance of LND in pN0 patients, relative to pNx patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings.